Agilus Diagnostics, one of India’s largest diagnostic networks and a subsidiary of Fortis Healthcare, has announced the installation of the Illumina NovaSeq X at its Mumbai reference laboratory. The launch was attended by Dr. Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare, Dr. Anand K., Managing Director & CEO, Agilus Diagnostics, and Deepak Narang, Chief Operating Officer, Agilus Diagnostics.
Genomic technologies are enabling earlier diagnosis and molecular insights into disease areas. Sequencing is used across applications including rare and inherited disorders, reproductive health, pharmacogenomics, infectious disease surveillance, and genome programmes.
The Illumina NovaSeq X adds to Agilus Diagnostics’ molecular testing portfolio through high-throughput sequencing and scalable analytics. The platform supports multi-omic outputs for use across clinical requirements. Through Agilus Diagnostics’ network, these services are available to clinicians and patients in metro and emerging markets.
The NovaSeq X operates with high-density flow cells and automation to support whole exome sequencing, whole genome sequencing, and multi-omic analysis. It is deployed for clinical decision-making and provides molecular data with defined turnaround timelines for physician use.
Dr. Ashutosh Raghuvanshi, MD & CEO, Fortis Healthcare, said, “Integrating advanced platforms like the Illumina NovaSeq X into clinical diagnostics is a pivotal step for India’s healthcare ecosystem. High-quality molecular insights are vital not only for oncology but also for diagnosing rare diseases, guiding targeted therapies, and advancing personalised and preventive care. Agilus’ investment brings cutting-edge science closer to patients and equips clinicians with actionable information to improve outcomes across a broad spectrum of conditions.”
Speaking at the launch, Dr. Anand K., Managing Director & CEO, Agilus Diagnostics, added, “The NovaSeq X marks a major step in our precision diagnostics journey. It strengthens our multi-omic capabilities across genomics and proteomics, enabling faster, high-resolution insights that power personalised medicine. This advancement brings us closer to delivering truly predictive and individualised care for patients across India.”
For clinicians and researchers, the increased sequencing capacity supports whole exome and whole genome testing for variant detection, genetic evaluation of inherited and rare disorders, reproductive and maternal health applications including carrier screening and prenatal testing, pharmacogenomic assessments to inform drug response and dosing, infectious disease sequencing for pathogen tracking and antimicrobial resistance insights, and liquid biopsy analysis alongside multi-omic studies for disease monitoring.
The platform supports Agilus Diagnostics’ portfolio of assays, including liquid biopsy panels, rare disease testing workflows, reproductive genomics, pharmacogenomic profiling, infectious disease sequencing, and multi-omic studies. Outputs from these assays are integrated into clinical pathways to generate reports for clinician use.
According to the company, the installation supports Agilus Diagnostics’ focus on precision diagnostics and predictive healthcare in India. The NovaSeq X enables readiness for population genomics, proteomic programmes, and longitudinal patient monitoring, while maintaining scale and nationwide access for next-generation diagnostics.